TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Home-base Kidney Care in Zuni Indians

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of diabetes~* Clinical diagnosis of microalbuminuria~* Must be living in a household with more than 1 living participant~* Age 21 to 80 years~* Must have negative pregnancy test in women of child-bearing potential~Exclusion Criteria:~* Life expectancy \< 1 year~* On dialysis~* With renal transplant~* Pregnancy or absence of reliable birth control in women of child-bearing potential~* Malignancy except non-melanoma skin cancer~* Blind~* Unwilling or unable to give informed consent.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Education and Lifestyle Coaching (Type: EXPERIMENTAL): Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence
- Usual care (UC) control arm (Type: NO_INTERVENTION): once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients~* aged 18 and older who meet criteria for fibromyalgia as defined by the American College of Rheumatology~* have a score of at least 4 on the average pain item of the Brief Pain Inventory (BPI) (modified short form) at visits 1 and 2~* all females must test negative for pregnancy at the time of enrollment~* have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.~Exclusion Criteria:~* have pain symptoms related to traumatic injury, structural rheumatic disease, or regional rheumatic disease that will interfere with interpretation of outcome measures~* have regional pain syndrome, multiple surgeries or failed back syndrome~* have confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease (i.e. systemic lupus erythematosus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): 60-120 mg, oral, every day, 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): oral, daily, 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of LP with predominant cutaneous involvement.~* IGA score of 3 or 4 at screening and baseline.~* Baseline LP-related Itch NRS score ≥ 4.~* Willingness to avoid pregnancy or fathering children.~Exclusion Criteria:~* Concurrent conditions and history of other diseases:~  1. Variants of LP deemed by the investigators to be inappropriate for topical treatment, including but not limited to predominant mucosal (such as oral or vaginal) LP.~ 2. Active ongoing inflammatory diseases of the skin other than LP that might confound the evaluation of LP lesions or compromise participant safety.~ 3. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton's syndrome), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of LP lesions or compromise participant safety.~ 4. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, or Wiskott-Aldrich syndrome).~ 5. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.~ 6. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chickenpox, clinically infected AD, or impetigo) within 1 week before baseline.~* Laboratory values outside of the protocol-defined criteria.~* Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.~* Other exclusive criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib cream (Type: EXPERIMENTAL): Ruxolitinib 1.5% cream BID for 16 weeks, followed by ruxolitinib cream BID 16-week open-label extension.
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Vehicle cream BID for 16 weeks, followed by ruxolitinib 1.5% cream BID in a 16-week open-label extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or biological remedies are offered to participate in the study. The protocol permits stratification for prednisolone usage, smoking habits and alcohol consumption.~Exclusion Criteria:~* age \<18 years;~* pregnancy,~* known intolerance of vaccine,~* ongoing infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- vaccinated patients (Type: ACTIVE_COMPARATOR): patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
- vaccinated controls (Type: ACTIVE_COMPARATOR): healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
- seasonal influenza vaccine (Type: ACTIVE_COMPARATOR): patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
- non-vaccinated controls (Type: ACTIVE_COMPARATOR): healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years to 45 years~* Pregnancy between 22 and 32 weeks of gestation~* Provides written informed consent~* Covered by French Social Security~Exclusion Criteria:~* Allergy to eggs or other components in the vaccine~* History of severe reactions following previous influenza vaccines~* H1N1 influenza (virologically documented) during the last 6 months~* Febrile episode within one week prior to vaccination~* Known HIV, HBV, HCV infection~* Multiple sclerosis~* History of Guillain-Barré syndrome~* Organ transplant recipient~* Neoplastic disease in the past 3 years~* Other vaccine within 3 weeks prior to study entry or planned within the month following the last injection~* Systemic corticosteroids,immunotherapy,chemotherapy~* Anticoagulant treatment~* Immunoglobulin or blood transfusion within the 3 months prior to enrollment in this study~* History of cardiac disease~* Chronic liver disease~* Diabetes before pregnancy~* History of premature delivery~* History of eclampsia~* Fetal morphologic abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Patients undergoing elective unilateral total hip replacement or a revision of at least 1 component of a total hip replacement.~* Patients who were willing and able to undergo bilateral ascending contrast venography~* Either sex, any race, 18 years and older~Key Exclusion Criteria~* Known or suspected bleeding or coagulation disorder in the patient or his or her first-degree relative~* Known or suspected history of heparin-induced thrombocytopenia~* Known coagulopathy~* Active bleeding or at high risk for bleeding~* Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days~* Active hepatobiliary disease~* Alcohol and/or substance abuse within the past year~* Any condition for which surgery or administration of an anticoagulant is contraindicated~* Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg~* Clinically significant laboratory abnormalities at the enrollment visit:~* Hemoglobin \<10 g/dL~* Platelet count \<100,000/mm\^3~* Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault~* Alanine aminotransferase or aspartate aminotransferase \>2\*upper limit of normal or a total bilirubin ≥ 1.5\*1 (unless an alternative causative factor such as Gilbert's syndrome was identified)~* Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with mechanical valves, warfarin eligible atrial fibrillation)~* Current use of dextrans or fibrinolytics~* Treatment with medications affecting coagulation or platelet function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban, 2.5 mg BID plus placebo (Type: ACTIVE_COMPARATOR): Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
- Enoxaparin, 40 mg QD plus placebo (Type: EXPERIMENTAL): Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of GAgP (AAP, 1999);~2. presence of ≥20 teeth;~3. presence of ≥ 6 sites presenting PD ≥ 5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to other two non-contiguous teeth);~4. good general health;~5. ≤ 35 years old; and~6. agree to participate in the study and sign a written informed consent. All subjects will be individually informed about the objectives, probable risks and benefits of the protocol treatment (according to Resolution nº196 of October 1996 and to the Professional Code of Dental Ethics - 179/93).~Exclusion Criteria:~1. pregnancy or lactating;~2. suffer from any systemic disease (e.g. cardiovascular disorders, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease;~3. took antimicrobials in the previous 6 months;~4. taking long-term anti-inflammatory drugs;~5. previous periodontal treatment within the last 12 months;~6. smokers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Amoxicillin and Metronidazole (Type: ACTIVE_COMPARATOR): In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
- Clarithromycin (Type: EXPERIMENTAL): In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Male External Catheters' Comparison of Comfort and Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult Male Patient ≥ 18 years old~2. Male anatomy at time of enrollment~3. Ability to speak and understand English~4. Willing to comply with all study procedures in this protocol~5. Able to independently void urine~6. Provision of signed and dated informed consent form~Exclusion Criteria:~1. Urinary incontinence which does not allow the subject to spontaneously void~2. Frequent episodes of bowel incontinence~3. Has Urinary Retention~4. Has any irritation, wound, open lesion, at the application site, on the genitalia, perineum, or sacrum~5. Recent surgery of the external urogenital tract, penis, or pubic area~6. Not able to comply with study procedures independently without required assistance~7. Any other condition that, in the opinion of the investigator, would preclude them from participating in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Sequence 1 (Type: OTHER): PureWick™ Male External Catheter is used first, followed by cross-over to Sage PrimoFit.
- Treatment Sequence 2 (Type: OTHER): The Sage PrimoFit™ is used first, followed by cross-over to PureWick MEC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early HIV Therapy in Patients With High CD4 Cell Counts

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection diagnosed by a rapid HIV test or any licensed ELISA test kit and documented in the participant's medical chart and re-verified at the time of study screening (hereafter: screen date).~* Most recent CD4+ cell count ≥ 250 cells/uL:~Arm A: CD4+ cell count 250-350 cells/uL Arm B: CD4+ cell count \>350 cells/uL~* Age ≥ 18 years.~* Residence within a 30 kilometer radius of the Bwizibwera HC-IV.~* Willing to initiate ART if the CD4+ cell count is ≥ 350 cells/uL.~* The following laboratory values obtained at the screening visit:~  * Absolute neutrophil count (ANC) ≥ 500 cells/uL~ * Hemoglobin ≥ 7.0 g/dL~ * Platelet count ≥ 50,000/uL~ * ALT (SGPT) ≤ 5 times greater than the upper limit of normal~ * Estimated glomerular filtration rate (eGFR) of ≥ 60 mL/minute by the Modification of Diet in Renal Disease (MDRD) formula:~eGFR = 186 \* Serum creatinine-1.154 \* Age-0.203 \* \[1.21 if African\] \* \[0.742 if female\]~* Ability to swallow oral medications.~* Ability and willingness of participant to give informed written consent.~Exclusion Criteria:~* Receipt at any time prior to study entry of \> 7 days cumulative treatment with any ARV or combination of ARVs, except ARVs taken for any length of time during pregnancy for the prevention of mother to child transmission (pMTCT) or ARVs taken for occupational exposure.~* For Arm B participants only: allergy/sensitivity to TDF, FTC, EFV, RTV, LPV or formulations of any of these three medications, or to co-formulated Truvada®.~* Active World Health Organization (WHO) HIV stage 3 or 4 illness~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
- Arm B (Type: ACTIVE_COMPARATOR): Treatment for HIV in participants with CD4+ cell counts \>350 cells/uL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Health Effects of SLT, Cigarette Smoking, and New Tobacco Products

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 18-70 years of age~* Smoking at least 10 cigarettes/day for at least one year~* Good physical and mental health as evidenced by a medical history with no unstable medical conditions.~Exclusion Criteria:~* Uncontrolled chronic disease or condition that requires medical attention during the course of the study~* Contraindications for nicotine replacement products: active ulcers, recent heart attack, heart disease or irregular heart beat, uncontrolled high blood pressure, or medication use that might affect tobacco use~* Current unstable psychiatric diagnoses or persons who currently are adjusting medication dose. (within the last 3 months)~* Subjects with current or recent (within 6 months) alcohol or drug abuse problem~* Other regular tobacco use such as regular cigar or pipe smoking~* Currently using other nicotine replacement products~* Chronic use of any drug that could interact with the study drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
- 2 (Type: EXPERIMENTAL): Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
- 3 (Type: EXPERIMENTAL): Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ocular hypertension or primary open-angle glaucoma in each eye~* Requires treatment with IOP-lowering medication in both eyes~Exclusion Criteria:~* Required chronic use of ocular medications during the study other than study medication~* Use of any corticosteroids within 30 days~* History of any traumatic eye surgeries~* Cataract surgery in the past 6 months~* Anticipated wearing of contact lenses during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Combination Therapy (Type: EXPERIMENTAL): Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
- Combigan® (Type: ACTIVE_COMPARATOR): Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete